We analyzed patients who had been followed up until 12 weeks after, designating as a population those who had visited our outpatient department with post-COVID-19 conditions as a main complaint. The study period started on August 1, 2021 and ended on June 1, 2022. The analysis only included the existing data; there were no exclusion criteria. General practitioners were in charge of the examination. We confirmed the presence or absence of symptoms in patients using a self-reported check sheet (original sheet) at the time of medical interview (Supplementary Material 1, www.jocmr.org). According to World Health Organization, a “post-COVID-19 condition occurs in individuals with a history of probable or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.” We analyzed all post-morbid symptoms, however, regardless of symptom duration. Regarding hair loss, we used a loupe to check the condition of the scalp. For patients with hypozincemia, we prescribed 50 mg of zinc acetate hydrate tablets to be taken twice a day and continued until the patient healed. (In Japan, doctors cannot prescribe zinc acetate hydrate because it is not covered by insurance unless it is hypozincemia.)